Nasdaq:GTBP
GT Biopharma, Inc.
A pre-revenue biopharmaceutical entity leveraging substantial paid-in capital to fund extensive R&D programs despite accumulating significant operating losses.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock for high-risk/high-reward biotech exposure given the massive $693.6M paid-in capital buffer that supports ongoing research initiatives. If the company secures strategic partnerships or achieves clinical milestones, the current negative equity could reprice significantly upward.
Bear Case
The stock faces existential risk due to zero revenue and a massive retained earnings deficit of over $695M which signals prolonged financial distress. With operating expenses at $14.4M against no income, the company is rapidly depleting its cash reserves without a clear path to profitability.
About GT Biopharma, Inc.
GT Biopharma Inc. is a biotechnology company focused on developing novel therapies, currently operating with no revenue generation. The firm's financial profile reflects high-burn characteristics typical of early-stage life sciences, utilizing significant cash reserves for research and development efforts in the US market.
Analysis
Management Discussion
Management has burned through approximately $13.2M in net income during 2024, with R&D spending at $5.8M while maintaining zero revenue. The company stabilized its cash position slightly with ending cash matching beginning cash of $4.0M after a net change of $3.0M from financing activities.
Industry Overview
The biopharmaceutical industry requires substantial upfront capital for R&D before any commercial return, making revenue-negative stages common but risky. Companies in this space must navigate regulatory hurdles and clinical trial failures while managing high operating costs typical of life sciences research.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $21.3M | $13.6M | $14.4M |
| Operating Income | $-21.3M | $-13.6M | $-14.4M |
| R&D | $8.8M | $6.5M | $5.8M |
| G&A | $12.4M | $7.1M | $8.6M |
| Stock-Based Comp | $7.7M | — | — |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $8.0K | $213.0K | — |
| Interest Income | $292.0K | $780.0K | $402.0K |
| Pre-Tax Income | $-21.3M | $-13.6M | $-14.4M |
| Income Tax | $-373.0K | $-6.0M | $-1.2M |
| Continuing Ops | $-20.9M | $-7.6M | $-13.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-20.9M | $-7.6M | $-13.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-20.9M | $-7.6M | $-13.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $16.6M | $14.1M | $4.2M |
| Cash & Equivalents | $5.7M | $1.1M | $4.0M |
| Marketable Securities | $10.8M | $12.9M | — |
| Prepaid Expenses | $54.0K | $84.0K | $188.0K |
| Other Current Assets | $0 | $0 | $93.0K |
| Long-Term Assets | $174.0K | $53.0K | $0 |
| Operating Leases | $165.0K | $53.0K | — |
| Other LT Assets | $9.0K | $0 | — |
| Total Assets | $16.7M | $14.1M | $4.2M |
| Current Liabilities | $4.9M | $6.6M | $5.9M |
| Accounts Payable | $3.1M | $4.3M | $3.9M |
| Current Leases | $110.0K | $58.0K | — |
| Other Current Liab | $19.0K | $1.1M | $252.0K |
| Long-Term Liabilities | $64.0K | $0 | $0 |
| LT Operating Leases | $64.0K | — | — |
| Other LT Liab | $0 | — | — |
| Total Liabilities | $5.0M | $6.6M | $5.9M |
| Shareholders' Equity | $11.7M | $7.5M | $-1.7M |
| Paid-In Capital | $686.2M | $689.5M | $693.6M |
| Retained Earnings | $-674.5M | $-682.1M | $-695.2M |
| Total L&E | $16.7M | $14.1M | $4.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-20.9M | $-7.6M | $-13.2M |
| Non-Cash Adjustments | $7.9M | $1.7M | $75.0K |
| Working Capital Changes | $-2.2M | $-3.0M | $183.0K |
| Cash from Operations | $-15.2M | $-8.9M | $-12.9M |
| Cash from Investing | $12.1M | $-2.0M | $12.9M |
| Cash from Financing | $-224.0K | $6.3M | $3.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-3.3M | $-4.6M | $3.0M |
| Beginning Cash | $9.0M | $5.7M | $1.1M |
| Ending Cash | $5.7M | $1.1M | $4.0M |
Frequently Asked Questions
How does GT Biopharma, Inc. make money?
The company operates primarily through a single innovation segment focused on drug discovery and development, with all financial activity currently directed toward research and general administrative overhead rather than commercial sales.
What are the main risks for GTBP?
Complete lack of revenue stream creates dependence on external financing or equity dilution; significant accumulated deficit of $695.2M indicates historical burn rates may threaten liquidity if fundraising stalls; negative operating profit and high G&A expenses suggest inefficient cost management for a non-commercial entity.
What is GTBP's competitive advantage?
Access to substantial paid-in capital of $693.6M provides long runway for R&D; low current liabilities relative to total assets suggest manageable short-term obligations; potential for high-value asset monetization upon successful clinical trials or acquisitions.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.